Clinical Study on Heavy Ion Therapy for Liver Cancer with Zero Out-of-Pocket Costs Fully Launched
Clinical Study on Heavy Ion Therapy for Liver Cancer with Zero Out-of-Pocket Costs Fully Launched
The Lanzhou Campus of Gansu Wuwei Cancer Hospital is the second clinical application center for heavy ion therapy with wholly owned Chinese intellectual property rights operated by Gansu Wuwei Cancer Hospital. Featuring the first Chinese heavy ion treatment system, the second Chinese heavy ion tumor treatment system was put into clinical operation on November 15, 2024, at the Lanzhou Campus of Gansu Wuwei Cancer Hospital. To date, our hospital has completed heavy ion and photon treatments for over 530 patients, covering diseases such as lung cancer, pancreatic cancer, liver cancer, and brain glioma.
To further support the high-quality development of China's heavy ion therapy, and building on previous efforts, we are deepening clinical application research and vigorously promoting the iterative upgrading of heavy ion treatment technology. We now launch the "Prospective, Single-Arm, Phase II Clinical Study of Carbon Ion Radiotherapy for the Curative Treatment of Early and Middle-Stage Hepatocellular Carcinoma," aiming to align with international standards, establish a clinical treatment standard for liver cancer using China's heavy ion system, and achieve better patient outcomes.
Prospective, Single-Arm, Phase II Clinical Study of Carbon Ion Radiotherapy for the Curative Treatment of Early and Middle-Stage Hepatocellular Carcinoma
Our hospital is conducting a Phase II clinical study of carbon ion radiotherapy for early and middle-stage hepatocellular carcinoma. Clinical trial number: WW-TLZ-2025-001. Carbon ion radiotherapy is an internationally advanced precision radiotherapy technique that can accurately destroy tumor cells while maximizing the protection of surrounding normal tissues. This study aims to evaluate the safety and efficacy of this technique and to explore optimized treatment options for liver cancer patients.
Selection Criteria
1. Aged 18–75 years, with pathologically confirmed hepatocellular carcinoma;
2. Tumor staged as early or middle-stage (BCLC stage A or B, with no extrahepatic metastasis);
3. Good liver function (Child-Pugh class A or B, with a score ≤ 7);
4. No prior liver radiotherapy, surgery, or other local curative treatment;
5. Willing to voluntarily participate in the study and able to comply with treatment and follow-up requirements.
The above criteria are the main eligibility criteria. Final determination of enrollment will be made by the investigator based on the trial protocol.
Patient Rights
1. The hospital will provide research funding to the expert team and cover the cost of heavy ion therapy for the patient.
2. A personalized treatment plan will be developed throughout the process by a multidisciplinary expert team (MDT) for liver cancer.
3. Regular follow-up monitoring will be provided for three years after treatment, along with priority access to new therapies.
Contact Information
Contact Person:
Lanzhou Campus of Gansu Wuwei Cancer Hospital
Qiao Hongmei: 13379389622
Gansu Wuwei Cancer Hospital, Lanzhou Campus
The Lanzhou Campus of Gansu Wuwei Cancer Hospital is the second clinical application center for heavy ion therapy with wholly owned Chinese intellectual property rights operated by Gansu Wuwei Cancer Hospital. Featuring the first Chinese heavy ion treatment system, the second Chinese heavy ion tumor treatment system was put into clinical operation on November 15, 2024, at the Lanzhou Campus of Gansu Wuwei Cancer Hospital. To date, our hospital has completed heavy ion and photon treatments for over 530 patients, covering diseases such as lung cancer, pancreatic cancer, liver cancer, and brain glioma.
Our hospital has established an exceptional talent system gathering elites, including an expert workstation led by 50 top industry authorities, such as Professor Shen Wenjiang, Lifetime Honorary Professor of the Department of Radiation Oncology at Peking University Health Science Center, and Professor Xu Bo, Standing Committee Member of the Chinese Society of Radiation Oncology. Professor Wang Junjie, Chairman of the Chinese Society of Radiation Oncology, serves as the Dean, providing strong technical support for heavy ion therapy.
Additionally, our hospital is equipped with a series of cutting-edge radiotherapy devices, including the Varian VitalBeam medical linear accelerator, the Elekta Infinity four-dimensional image-guided radiotherapy linear accelerator, a 3.0T simulation positioning MRI, a GE 256-row high-end CT, and the Varian Iridium-192 imported brachytherapy afterloader. These hardware facilities lay a solid foundation for heavy ion therapy, ensuring high efficiency and precision throughout the treatment process.
With the goal of building a comprehensive, full-life-cycle tumor treatment system, our hospital has established departments including the Department of Radiation Oncology, Department of Medical Oncology/Hematology, Department of Surgical Oncology, Department of Integrative Traditional Chinese and Western Medicine for Cancer Rehabilitation, Minimally Invasive Intervention Center, Department of Critical Care Medicine, and Digestive Endoscopy Center. We provide heavy ion radiotherapy, photon radiotherapy, chemotherapy, minimally invasive interventional therapy, and comprehensive medical and surgical treatments for cancer.
Our hospital is equipped with advanced diagnostic technology and equipment. We have set up medical technology departments such as the Department of Medical Imaging, Department of Laboratory Medicine, Department of Ultrasound Medicine, Blood Bank, and Hematology Center Laboratory, offering CT/MRI imaging diagnosis, medical laboratory tests, ultrasound diagnosis and interventional procedures, and bone marrow cell morphology examinations to meet patients' diagnostic needs.
The Minimally Invasive Intervention Center is equipped with a radioactive I125 tumor brachytherapy system and body implantation navigation and positioning system, GE digital angiography system, microwave thermocoagulation therapy device, and argon-helium cryoablation therapy device, enabling precise treatment for cancer patients through embolization, ablation, and brachytherapy.
